Cargando…
Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway
Metastatic renal cell carcinoma (RCC) is associated with poor prognosis. Ras protein activator like 2 (RASAL2) protein has been previously demonstrated to serves as a tumor suppressor in a variety of malignancies. Therefore, the aim of the present study was to investigate the role of RASAL2 in RCC....
Autores principales: | Wang, Sen, Hao, Xiaomin, He, Sai, Liu, Changli, Wang, Qilong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571372/ https://www.ncbi.nlm.nih.gov/pubmed/33093889 http://dx.doi.org/10.3892/etm.2020.9280 |
Ejemplares similares
-
RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial–mesenchymal transition via MAPK/SOX2 pathway in bladder cancer
por: Hui, Ke, et al.
Publicado: (2017) -
The expression and function of RASAL2 in renal cell carcinoma angiogenesis
por: Hui, Ke, et al.
Publicado: (2018) -
CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation
por: Lin, Zigen, et al.
Publicado: (2022) -
Correction for: CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation
por: Lin, Zigen, et al.
Publicado: (2023) -
Hypermethylation of RASAL1: A Key for Renal Fibrosis
por: Mao, Yuanjie
Publicado: (2014)